Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.
|Translated title of the contribution||去整合蛋白變異體及其醫藥用途|
|Patent number||EP 2124548|
|Publication status||Published - 2009 Dec 2|